Related Experiment Video
Updated: May 16, 2026
11:39
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
What do we do with chronic lymphocytic leukemia with 17p deletion?
L Sellner1, S Denzinger, S Dietrich
1Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Current Hematologic Malignancy Reports
|November 29, 2012
Summary
Patients with chronic lymphocytic leukemia (CLL) and TP53 gene alterations face poor prognoses. This review explores current and emerging treatments, including novel agents and stem cell transplantation, for this high-risk group.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Chronic lymphocytic leukemia (CLL) with 17p deletion or TP53 mutations presents a significant clinical challenge with poor outcomes.
- Standard chemo-immunotherapy offers limited efficacy in these high-risk patients.
Purpose of the Study:
- To review current treatment strategies and experimental approaches for CLL patients with TP53 alterations.
- To highlight novel agents and future perspectives for managing this challenging patient population.
Main Methods:
- Literature review of current treatment options.
- Discussion of experimental approaches in clinical trials.
- Emphasis on novel agents and future management strategies.
Main Results:
- Conventional chemo-immunotherapy shows suboptimal results in TP53-altered CLL.
- Allogeneic stem cell transplantation offers potential for long-term remission.
- Novel agents are emerging with potential to alter clinical practice.
Conclusions:
- Optimal treatment for CLL with 17p deletion or TP53 mutations remains a critical unmet need.
- Emerging therapies and stem cell transplantation represent promising avenues for improving outcomes.
- Further research into novel agents is crucial for managing high-risk CLL patients.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...